According to the report published by Allied Market Research, the global schizophrenia drugs market generated $7.16 billion in 2021 and is estimated to hit $12.53 billion by 2031, registering a CAGR of 5.8% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.
๐๐ก๐ ๐ค๐๐ฒ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฉ๐ฅ๐๐ฒ๐๐ซ๐ฌ ๐๐ง๐๐ฅ๐ฒ๐ณ๐๐ ๐ข๐ง ๐ญ๐ก๐ ๐ ๐ฅ๐จ๐๐๐ฅ ๐ฌ๐๐ก๐ข๐ณ๐จ๐ฉ๐ก๐ซ๐๐ง๐ข๐ ๐๐ซ๐ฎ๐ ๐ฌ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ซ๐๐ฉ๐จ๐ซ๐ญ ๐ข๐ง๐๐ฅ๐ฎ๐๐
Pfizer Inc., AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck KGAA, Minerva Neurosciences, Novartis AG, Reliance, Sumitomo Dainippon, Takeda Pharmaceuticals, Vanda Pharmaceuticals, Alkermes
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ-ย https://www.alliedmarketresearch.com/request-sample/17470
“Alarming rise in prevalence of mental diseases, growing awareness about mental health, fevorable government policies to promote mental health, and increase in product launch contribute toward the growth of the global schizophrenia drugs market during the forecast period. ”
Additionally, the increase in the geriatric population is driving the growth of the market. Elderly people are more prone to mental problems such as neurological diseases and Alzheimer’s disease. For example, in 2021, according to the Alzheimer’s Association report, about 6.2 million Americans aged 65 and older will suffer from Alzheimer’s dementia. In addition, the rise in life stress and the increase in stress related to the workplace is contributing to the growth of the market. Chronic mental stress that causes mental illness, such as psychotic behavior, hallucinations and delusions.
๐๐๐ฉ๐จ๐ซ๐ญ ๐๐จ๐ฏ๐๐ซ๐๐ ๐ & ๐๐๐ญ๐๐ข๐ฅ๐ฌ:
๐๐๐ ๐ฆ๐๐ง๐ญ๐ฌ ๐๐จ๐ฏ๐๐ซ๐๐ : Treatment, Distribution Channel, Therapeutic Class, and Region
๐๐ซ๐ข๐ฏ๐๐ซ๐ฌ : Increase in prevalence of schizophrenia and mental disturbances such as anxiety and depression
Rise in awareness about mental health and schizophrenia treatments, and increase in acceptability of schizophrenia drugs by medical practitioners
Surge in mental health awareness programs by government and non-government organizations
๐๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ : Increase in R&D activity for advancements in anti-psychotic drugs and number of product launches and approvals
Rise in number of clinical trials for the development of novel schizophrenia treatments
Rise in number of industrial collaborations in drug development
๐๐๐ฌ๐ญ๐ซ๐๐ข๐ง๐ญ๐ฌ : Lack of appropriate healthcare infrastructure for mental health
๐๐ฆ๐ฉ๐๐๐ญ ๐จ๐ ๐๐จ๐ฏ๐ข๐-19 ๐จ๐ง ๐๐๐ก๐ข๐ณ๐จ๐ฉ๐ก๐ซ๐๐ง๐ข๐ ๐๐ซ๐ฎ๐ ๐ฌ ๐๐๐ซ๐ค๐๐ญ-
โข The Covid-19 outbreak negatively impacted the global schizophrenia drugs market. Due to implementation of lockdowns and imposition of stringent measures by governments across the globe, production and manufacturing activities came to a halt.
โข The pharmaceutical industry faced difficulties in focusing on R&D activities regarding schizophrenia drugs development as the entire healthcare industry was focused on life saving and COVID-19 related products.
โข There were delays in product approvals and launches which further restricted the expansion of the market. Furthermore, most of the clinical trials were postponed to avoid spread of infections, thus slowing down the drug development process.
โข However, the pandemic led to the increase in mental health problems worldwide and the healthcare sector has been restructured to provide safer healthcare facilities. Hence, the schizophrenia drugs market is anticipated to grow in the coming years.
๐๐๐ญ ๐๐๐ญ๐๐ข๐ฅ๐๐ ๐๐๐๐๐-19 ๐ข๐ฆ๐ฉ๐๐๐ญ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐จ๐ง ๐ญ๐ก๐ ๐๐๐ก๐ข๐ณ๐จ๐ฉ๐ก๐ซ๐๐ง๐ข๐ ๐๐ซ๐ฎ๐ ๐ฌ ๐๐๐ซ๐ค๐๐ญ-ย https://www.alliedmarketresearch.com/request-for-customization/17470?reqfor=covid
๐๐ฒ ๐๐๐ ๐ข๐จ๐ง : North America (U.S., Canada, Mexico)
Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
๐
๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐?
Q1. What are the key trends in the Schizophrenia Drugs market report?
Q2. What are the market values / growth % of emerging countries?
Q3. Which is the largest regional market for Schizophrenia Drugs?
Q4. Which are the top companies to hold the market share in Schizophrenia Drugs?
Q5. What is the market value of Schizophrenia Drugs market in 2022?
Q6. Which is base year calculated in the Schizophrenia Drugs market report?
Q7. What is the total market value of Schizophrenia Drugs market report ?
Q8. What would be forecast period in the market report?
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ-ย https://www.alliedmarketresearch.com/purchase-enquiry/17470
๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐ข๐ง ๐๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ :
๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐ก๐ข๐ฌ๐ญ๐จ๐๐ก๐๐ฆ๐ข๐ฌ๐ญ๐ซ๐ฒ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก โ 2031 https://www.alliedmarketresearch.com/immunohistochemistry-market-A11199
๐๐๐ซ๐๐ข๐๐ ๐ซ๐๐ก๐๐๐ข๐ฅ๐ข๐ญ๐๐ญ๐ข๐จ๐ง ๐ฆ๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก โ 2031 https://www.alliedmarketresearch.com/cardiac-rehabilitation-market-A11270
๐๐จ๐ฌ๐ฉ๐ข๐ญ๐๐ฅ ๐๐๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก โ 2031 https://www.alliedmarketresearch.com/hospital-beds-market-A15374
๐๐ซ๐ญ๐ก๐จ๐๐ข๐จ๐ฅ๐จ๐ ๐ข๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค โ 2025 https://www.alliedmarketresearch.com/orthobiologics-market
๐๐๐ง๐๐จ๐ง ๐๐๐ฉ๐๐ข๐ซ ๐๐๐ซ๐ค๐๐ญ โ 2031 โ https://www.alliedmarketresearch.com/tendon-repair-market-A17088